Clinical trials query results
From Health Canada
| Drug name | CTA protocol title | Medical condition | Study population | Trial status |
|---|---|---|---|---|
| DNL310 | A PHASE 2/3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DNL310 VS IDURSULFASE IN PEDIATRIC PARTICIPANTS WITH NEURONOPATHIC OR NON-NEURONOPATHIC MUCOPOLYSACCHARIDOSIS TYPE II | MUCOPOLYSACCHARIDOSIS TYPE II (MPS II) | PEDIATRIC | ONGOING |
| DNL310 | AN OPEN-LABEL EXTENSION TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DNL310 IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS TYPE II (MPS II) FROM STUDY DNLI-E-0002 OR STUDY DNLI-E-0007 | MUCOPOLYSACCHARIDOSIS TYPE II (MPS II) | PEDIATRIC,ADULT FEMALE,ADULT MALE | ONGOING |
| HMI-203 / DEXAMETHASONE / TACROLIMUS ER (ADVAGRAF) | A PHASE 1 OPEN-LABEL DOSE ESCALATION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HMI-203 IN ENZYME REPLACEMENT THERAPY (ERT)-TREATED ADULTS WITH MUCOPOLYSACCHARIDOSIS TYPE II (MPS II) (JUMPSTART TRIAL) | MUCOPOLYSACCHARIDOSIS TYPE II (MPS II) | ADULT MALE | CLOSED |
| HUMIRA | EFFECT OF ADALIMUMAB ON MUSCULOSKELETAL DISEASE IN MUCOPOLYSACCHARIDOSIS TYPES I, II, IVA AND VI | MUCOPOLYSACCHARIDOSIS IVA (MORQUIO SYNDROME),MUCOPOLYSACCHARIDOSIS TYPE II (MPS II) | PEDIATRIC,ADULT FEMALE,ADULT MALE | PENDING |
| RGX-121 / RAPAMUNE / PROGRAF / PREDNISOLONE / MEDROL | A PHASE 1/2/3 MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF RGX-121 IN PEDIATRIC SUBJECTS WITH MPS II (HUNTER SYNDROME) | HUNTER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE II (MPS II) | PEDIATRIC | CLOSED |